Chimerix
Chimerix discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid prodrug technology, ProLipTagTM, Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. Known drugs can be modified to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Chimerix is applying its technology towards the discovery and development of oral drugs for the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection and viral hepatitis.
www.chimerix-inc.com
VaxInnate
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company’s breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy, avoiding many of the challenges and pitfalls of egg-based or cell-culture influenza vaccine production. VaxInnate’s technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines – key issues facing the clinical and public health communities.
www.vaxinnate.comMeet Specializing Partners
Brent Ahrens
Stephen Bloch
Wende Hutton
Mickey Kim
Seth Rudnick
News
Downloads
Canaan Brochure [pdf, 1.2MB]
Healthcare Factsheet [pdf, 1.16MB]
© 2008 Canaan Partners